Breast Cancer Clinical Trials in Houston, Texas

76 studies are recruiting for breast cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 3

  1. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    6 in total
    Run by
    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

  2. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  3. ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

    This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast l…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    5 in total
    Run by
    ARTIDIS AG

    See if you can join NCT06085833 on ClinicalTrials.gov

  4. Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

    To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detecte…

    Stage
    Not phased
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05042687 on ClinicalTrials.gov

  5. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Next Oncology, Houston, Texas
    Locations
    18 in total
    Run by
    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

  6. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  7. Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

    To hypnosedation alone given before and during surgery on reducing opioid use after surgery compared to standard general anesthesia given alone or with hypnosedation.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05766891 on ClinicalTrials.gov

  8. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

    The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Md Anderson Cancer Center, Houston, Texas
    Locations
    18 in total
    Run by
    UMC Utrecht

    See if you can join NCT04075305 on ClinicalTrials.gov

  9. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  10. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Baylor St. Luke's Medical Center, Houston, Texas
    Run by
    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

  11. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oncology Consultants, P.A., Houston, Texas
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  12. Converting HR+ Breast Cancer Into an Individualized Vaccine

    Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms…

    Stage
    Phase 2
    Ages
    18 to 90
    Site
    Houston Methodist Cancer Center, Houston, Texas
    Locations
    8 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT03804944 on ClinicalTrials.gov

  13. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

    Stage
    Not phased
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    58 in total
    Run by
    Exact Sciences Corporation

    See if you can join NCT06401421 on ClinicalTrials.gov

  14. Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

    The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: * Will cancer come back in …

    Stage
    Not phased
    Ages
    50 and older
    Site
    Baylor St Luke's Medical Centre, Houston, Texas
    Locations
    9 in total
    Run by
    Breast Cancer Trials, Australia and New Zealand

    See if you can join NCT06445738 on ClinicalTrials.gov

  15. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

  16. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Houston, Texas
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  17. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas M.D. Anderson Cancer Center, Houston, Texas
    Locations
    37 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

  18. TRUDI: TDXD+Durva in HER2+/Low IBC

    The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of th…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    3 in total
    Run by
    Filipa Lynce, MD

    See if you can join NCT05795101 on ClinicalTrials.gov

  19. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Texas Oncology - Memorial City, Houston, Texas
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

  20. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

    The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The stu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Biotheryx Investigative Site, Houston, Texas
    Locations
    6 in total
    Run by
    Biotheryx, Inc.

    See if you can join NCT06515470 on ClinicalTrials.gov

  21. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to char…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    4 in total
    Run by
    AtlasMedx, Incorporated

    See if you can join NCT04503265 on ClinicalTrials.gov

  22. Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

    The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving c…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Harris Health System - Smith Clinic, Houston, Texas
    Locations
    2 in total
    Run by
    Baylor Breast Care Center

    See if you can join NCT05020860 on ClinicalTrials.gov

  23. BostonGene and Exigent Genomic INsight Study

    The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Oncology Consultants, Houston, Texas
    Locations
    7 in total
    Run by
    BostonGene

    See if you can join NCT06272864 on ClinicalTrials.gov

  24. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Health Houston, Houston, Texas
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

  25. Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response

    This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to cancer treatment and predicting which patients continue on in t…

    Stage
    Not phased
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    3 in total
    Run by
    Sunnybrook Health Sciences Centre

    See if you can join NCT04134780 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.